Abstract 2142
Background
Renal cell carcinoma (RCC) is considered an immunogenic cancer with a high frequency of indel mutations, immuno-oncological (IO) sensitivity, and infiltration of T cells. Because natural killer (NK) cells are a lesser known population compared to their T cell counterparts, we aimed to investigate the intratumoral phenotype of the cells to assess the overall immune landscape of RCC.
Methods
The tumor, matching peripheral blood (PB) and healthy kidney tissue samples were obtained from 40 RCC patients that underwent radical nephrectomy and were phenotyped using multi-parameter flow cytometry and a comprehensive immunostaining panel containing 56 fundamental markers to cancer immunology.
Results
Using hierarchical clustering and correlation analysis, we discovered that our cohort clustered into two distinct subgroups defined by the abundance of NK cells from the intratumoral lymphocyte population, defined as NKhigh (n = 17; mean 24.3%) and NKlow (n = 18; mean 7.5%). Consequently, an increased abundance of NK cells correlated with a lower expression of PD-1, particularly in the CD8+ T cells (r=-0.5722, p = 0.0003), but not with LAG-3. Contrastingly, clinical parameters such as tumor grade, gender and age did not differ between the two NK subgroups. However, patients with high NK cell abundance significantly had more often necrosis present in the tumors (p = 0.04). We also independently phenotyped two regions of the same tumor sample (n = 10) to compare the periphery and core lymphocytes. Surprisingly, both spatially different regions displayed similar quantities of immune cell populations and immunophenotypic markers. Overall, the tumor immune landscape in RCC resulted in a proportion of tumors carrying a higher abundance of NK cells than their T cell-rich corresponding PB and healthy tissue samples, which supports our findings that a proportion of tumors accumulate NK cells.
Conclusions
Our study has led to the discovery of two distinct RCC tumoral NK cell subgroups, NKhigh and NKlow. Next, we aim to further explore the transcriptional differences of the two subgroups with ongoing bulk RNA sequencing (RNAseq). Furthermore, prospective single-cell RNA sequencing (sc-RNAseq) will be carried out to investigate the immunological heterogeneities in higher resolution.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
University of Helsinki, Hematology Research Unit Helsinki.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4614 - Predictors of Response to Checkpoint Inhibitors in Naïve and Ipilimumab-Refractory Melanoma
Presenter: Domenico Mallardo
Session: Poster Display session 3
Resources:
Abstract
2901 - IFN-γ/IL-10 ratio as predictive biomarker for response to anti-PD-1 therapy in metastatic melanoma patients
Presenter: Emilio Giunta
Session: Poster Display session 3
Resources:
Abstract
2306 - Multiplex Chromogenic Immunohistochemistry (IHC) for Spatial Analysis of Checkpoint-Positive Tumor Infiltrating Lymphocytes (TILs)
Presenter: Scott Ely
Session: Poster Display session 3
Resources:
Abstract
1678 - The role of PD-L1 expression as a predictive biomarker in advanced renal cell carcinoma: a meta-analysis of randomized clinical trials.
Presenter: Alberto Carretero-Gonzalez
Session: Poster Display session 3
Resources:
Abstract
5138 - Radiomic Features as a Non-invasive Biomarker to Predict Response to Immunotherapy in Recurrent or Metastatic Urothelial Carcinoma
Presenter: Kye Jin Park
Session: Poster Display session 3
Resources:
Abstract
5800 - Integrative combination of high-plex digital profiling techniques and cluster analysis to reveal complex immune biology in the tumor microenvironment of mesothelioma
Presenter: Carmen Ballesteros-Merino
Session: Poster Display session 3
Resources:
Abstract
5736 - Predictive factors of response to immunotherapy in 198 patients with metastatic non-microcytic lung cancer (mNSCLC): real world data from 2 university hospitals in Spain
Presenter: Juan Felipe Cordoba Ortega
Session: Poster Display session 3
Resources:
Abstract
5645 - Evaluating Lung CT Density Changes Among Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Treated with Thoracic Radiotherapy (TRT) alone or TRT Followed by Combined Ipilimumab (IPI) and Nivolumab (NIVO).
Presenter: Kujtim Latifi
Session: Poster Display session 3
Resources:
Abstract
1540 - Immuno-oncology therapy biomarkers differences between polyoma-virus positive and negative Merkel cell carcinomas
Presenter: Zoran Gatalica
Session: Poster Display session 3
Resources:
Abstract
4538 - Can we improve patient selection for phase 1 clinical trials (Ph1) based on Immuno-Oncology score prognostic index (VIO)?
Presenter: Ignacio Matos Garcia
Session: Poster Display session 3
Resources:
Abstract